Processa Pharmaceuticals Inc. (PCSA)
NASDAQ: PCSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PCSA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.37M
- EPS (TTM)
- -$68.29
- Dividend yield
- None
- 52-week range
- 1.04 – 8.88
- Day range
- 1.39 – 1.66
- Volume / Avg
- 69.95K / 79.50K
- Beta
- —
- Shares outstanding
- 2.80M
52-week range
PCSA stock today
Processa Pharmaceuticals (PCSA) closed at $1.56 on Nov 20, down 7.69% (-$0.13), versus the S&P 500's 3.70% decline. Shares are 82.4% below their 52-week high of $8.88 and 49.9% above the 52-week low of $1.04, near the bottom of the past year's range. Processa Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$68.29), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Processa Pharmaceuticals
Company profileProcessa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. George K. Ng Esq., J.D.
- Headquarters
- Vero Beach, FL
- Employees
- 12
- Website
- processapharmaceuticals.com
Financial highlights
Full financialsProcessa Pharmaceuticals reported a net loss of $13.6 million, compared with a loss of $11.9 million a year earlier. Diluted earnings per share came in at -$10.36.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 |
| Growth | — | — | — | — | — |
| Net income | $-13.56M | $-11.85M | $-11.12M | $-27.42M | $-11.43M |
| EPS (diluted) | $-10.36 | $-96.78 | $-8.48 | $-34.05 | $-0.75 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-61.58 vs —
PCSA news
All PCSA news- Processa Pharmaceuticals, Inc. Appoints Gregory J. Flesher as Chief Operating Officer and Announces Key Leadership AdditionsNasdaq
- Processa Pharmaceuticals Announces Key Leadership AppointmentsGlobeNewswire
- Processa Pharmaceuticals, Inc. Appoints Dr. Sheila Gujrathi as Executive Chair and Announces FDA Clearance of Phase 2 IND for VT-7208Nasdaq
- Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya TherapeuticsGlobeNewswire
Processa Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CANFCan-Fite Biopharma Ltd ADR | 1.44 | -2.34% | $4.35M | vs PCSA |
| PULMPulmatrix Inc. | 1.27 | -10.56% | $4.64M | vs PCSA |
| SCNXScienture Holdings Inc. | 2.28 | -6.45% | $4.07M | vs PCSA |
| BLRXBioLineRx Ltd. ADR | 0.9639 | -8.20% | $4.80M | vs PCSA |
| LTRNLantern Pharma Inc. | 0.245 | -13.73% | $3.89M | vs PCSA |
| ALZNAlzamend Neuro Inc. | 0.7758 | -23.94% | $3.74M | vs PCSA |
| SILOSilo Pharma Inc. | 1.71 | -9.04% | $3.69M | vs PCSA |
| BGMSBio Green Med Solution Inc. | 0.553 | -9.48% | $3.66M | vs PCSA |
Indexes, lists and sector
Processa Pharmaceuticals stock FAQ
What is Processa Pharmaceuticals's stock price today?
PCSA last traded at $1.56 as of Nov 20, 4:00 PM EST, down 7.69% on the day. Prices are delayed at least 15 minutes.
Who is Processa Pharmaceuticals's CEO?
Mr. George K. Ng Esq., J.D. is the chief executive officer of Processa Pharmaceuticals Inc., which has about 12 employees.
What is the PCSA 52-week high?
The 52-week high for PCSA is $8.88 and the 52-week low is $1.04. The stock is currently 82.4% below its high.